These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31602692)

  • 1. Effect of Plasma Protein Binding on the Pharmacokinetics of Erdafitinib: Results of an Integrated Cross-Study Analysis.
    Li LY; Guo Y; Gonzalez M; Ouellet D
    J Clin Pharmacol; 2020 Mar; 60(3):391-399. PubMed ID: 31602692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies.
    Dosne AG; Valade E; Stuyckens K; Li LY; Ouellet D; Perez-Ruixo JJ
    J Clin Pharmacol; 2020 Apr; 60(4):515-527. PubMed ID: 31742712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
    Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.
    De Zwart L; Snoeys J; Jacobs F; Li LY; Poggesi I; Verboven P; Goris I; Scheers E; Wynant I; Monshouwer M; Mamidi RNVS
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1107-1118. PubMed ID: 34273250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.
    Nishina T; Takahashi S; Iwasawa R; Noguchi H; Aoki M; Doi T
    Invest New Drugs; 2018 Jun; 36(3):424-434. PubMed ID: 28965185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib.
    Tosca EM; Terranova N; Stuyckens K; Dosne AG; Perera T; Vialard J; King P; Verhulst T; Perez-Ruixo JJ; Magni P; Poggesi I
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):117-128. PubMed ID: 34786600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants.
    Jaiprasart P; Hellemans P; Jiao JJ; Dosne AG; De Meulder M; De Zwart L; Brees L; Zhu W
    Clin Pharmacol Drug Dev; 2024 Aug; 13(8):852-860. PubMed ID: 38740493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.
    Scheers E; Borgmans C; Keung C; Bohets H; Wynant I; Poggesi I; Cuyckens F; Leclercq L; Mamidi RNVS
    Xenobiotica; 2021 Feb; 51(2):177-193. PubMed ID: 32902324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
    Bahleda R; Italiano A; Hierro C; Mita A; Cervantes A; Chan N; Awad M; Calvo E; Moreno V; Govindan R; Spira A; Gonzalez M; Zhong B; Santiago-Walker A; Poggesi I; Parekh T; Xie H; Infante J; Tabernero J
    Clin Cancer Res; 2019 Aug; 25(16):4888-4897. PubMed ID: 31088831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Erdafitinib on the Pharmacokinetics of Midazolam and Metformin in Patients With Advanced Solid Tumors Harboring FGFR Gene Alterations.
    Zhu W; Baig M; Naini V; De Meulder M; Akapame S; De Zwart L; Haddish-Berhane N; Triantos S
    Clin Pharmacol Drug Dev; 2024 Oct; 13(10):1164-1176. PubMed ID: 39044705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure-QTc in patients with advanced or refractory solid tumors.
    Valade E; Dosne AG; Xie H; Kleiman R; Li LY; Perez-Ruixo JJ; Ouellet D
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):621-633. PubMed ID: 31280362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPLC-UV determination of erdafitinib in mouse plasma and its application to pharmacokinetic studies.
    Elawady T; Khedr A; El-Enany N; Belal F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 May; 1171():122629. PubMed ID: 33752054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of alpha 1-acid glycoprotein to species difference in lincosamides-plasma protein binding kinetics.
    Son DS; Osabe M; Shimoda M; Kokue E
    J Vet Pharmacol Ther; 1998 Feb; 21(1):34-40. PubMed ID: 9507455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facing the Facts of Altered Plasma Protein Binding: Do Current Models Correctly Predict Changes in Fraction Unbound in Special Populations?
    Al-Qassabi J; Tan SPF; Phonboon P; Galetin A; Rostami-Hodjegan A; Scotcher D
    J Pharm Sci; 2024 Jun; 113(6):1664-1673. PubMed ID: 38417790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique Hydrolysis of an Ester-Type Prodrug of Levodopa in Human Plasma: Relay-Type Role Sharing between Alpha-1 Acid Glycoprotein and Human Serum Albumin.
    Kono K; Fukuchi Y; Okawa H; Nunoya KI; Imawaka H; Watanabe H; Maruyama T
    Mol Pharm; 2019 Oct; 16(10):4131-4138. PubMed ID: 31433646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics.
    Huang Z; Ung T
    Curr Drug Metab; 2013 Feb; 14(2):226-38. PubMed ID: 23092311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting Drug Binding to Human Serum Albumin and Alpha One Acid Glycoprotein in Diseased and Age Patient Populations.
    McNamara PJ; Meiman D
    J Pharm Sci; 2019 Aug; 108(8):2737-2747. PubMed ID: 30905706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of drug binding with alpha
    Beeram SR; Zhang C; Suh K; Clarke WA; Hage DS
    J Chromatogr A; 2021 Jul; 1649():462240. PubMed ID: 34034105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of Aripiprazole With Human α
    Nishi K; Sakurama K; Kobashigawa Y; Morioka H; Udo N; Hashimoto M; Imoto S; Yamasaki K; Otagiri M
    J Pharm Sci; 2019 Dec; 108(12):3911-3916. PubMed ID: 31520646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variations of orosomucoid genes associated with serum alpha-1-acid glycoprotein level and the pharmacokinetics of paclitaxel in Japanese cancer patients.
    Katori N; Sai K; Saito Y; Fukushima-Uesaka H; Kurose K; Yomota C; Kawanishi T; Nishimaki-Mogami T; Naito M; Sawada J; Kunitoh H; Nokihara H; Sekine I; Ohe Y; Yoshida T; Matsumura Y; Saijo N; Yamamoto N; Okuda H; Tamura T
    J Pharm Sci; 2011 Oct; 100(10):4546-59. PubMed ID: 21638284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.